drugset
drugset / Trial / NCT05720559

Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection

NCT05720559 ↗

Phase 2 Not yet recruiting 100 enrolled Liaoning Cancer Hospital & Institute
RandomizedSingle-groupOpen-labelTreatment

Summary

In this study, the Quintuple method was applied for early intervention of prehepatic CTC-positive bowel cancer patients without dominant liver metastasis, aiming to explore the blocking effect of the Quintuple method on the metachronous liver metastases of colorectal cancer. A one-arm randomized clinical trial was conducted, and the patients were grouped according to their treatment methods. The patients with metachronous liver metastases were used as the end point of the experiment to evaluate the blocking effect of quintuple therapy.

Timeline

Start
2023-03-01
Primary completion
2026-03-01
Completion
2026-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1000 mg/m2 Oral
Subject Cetuximab Monoclonal antibody 250 mg/m2 Intravenous
Subject Metronidazole Small molecule 0.4 g —
Subject S-1 Small molecule 20 mg Oral
Subject Vitamin A Unknown 25000 iu —
Subject folic acid Other / unclassified 0.4 mg —
Background Oxaliplatin Small molecule 130 mg/m2 Intravenous

Indications

No indication recorded.